Section 33, paragraph 2 of Act No 378/2007 Coll., on Pharmaceuticals and on Amendments to Some Related Acts (hereinafter referred to as the "Act on Pharmaceuticals") stipulates the obligation of the marketing authorisation holder to report to SÚKL:
- The date of actual placement of a medicinal product on the market in the Czech Republic broken down by pack size and type of packaging; no later than two months after its actual placing on the market
- The date of suspension or termination of marketing of the medicinal product in the Czech Republic no later than two months in advance thereof; where exceptional circumstances arise, such notification may be made no later than concurrently with the actual suspension or termination of marketing of the medicinal product in the Czech Republic;
- Forthwith the date of resumed marketing of the medicinal product.
For these purposes, SÚKL has prepared an electronic report form:
Please authorise the data you have entered into the form by means of a certified electronic signature. Authorised data shall be securely sent from the form to SÚKL database without any further intervention on the part of the user being necessary. Receipt of the report and compliance with the notification duty shall be confirmed for the marketing authorisation holder by an automatically generated form confirming the receipt of the report.
Reports on the placement of medicinal products on the market in the Czech Republic, suspension or termination of their marketing or their resumed marketing in the Czech Republic are published by SÚKL on an ongoing basis (please refer to the Overview of notifications) in order to provide the public with current information on the actual availability of medicinal products. These data are important especially for doctors to be able to secure the treatment of patients in clinical practice, for pharmacists in the dispensing of medicinal products and provision of relevant information to patients.
Please note that pursuant to Section 105, paragraph 5(c) of the Act on Pharmaceuticals, failure to comply with the above-mentioned notification duties may result in the marketing authorisation holder committing an administrative offence for which a fine of the max. of 2 000,000 CZK, pursuant to section 107, par. 1 (c ) of the Act on Pharmaceuticals, may be imposed.
- Questions and Answers on Issues Regarding the Placement a Medicinal Product onto the Market_20200615.pdf, (320.71 kB)
September 15 2009
Update: June 15 2020